Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
12.14
+0.13 (1.08%)
At close: May 13, 2026, 4:00 PM EDT
12.01
-0.13 (-1.07%)
After-hours: May 13, 2026, 7:59 PM EDT
Ernexa Therapeutics Employees
As of December 31, 2025, Ernexa Therapeutics had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,629,143
Market Cap
14.16M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | 1 | 16.67% | 5 | 2 |
| Dec 31, 2024 | 6 | -2 | -25.00% | 6 | 0 |
| Dec 31, 2023 | 8 | -1 | -11.11% | 8 | 0 |
| Dec 31, 2022 | 9 | -1 | -10.00% | 9 | 0 |
| Dec 31, 2021 | 10 | 0 | - | 10 | 0 |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioLineRx | 24 |
| Theriva Biologics | 16 |
| Genenta Science | 9 |
| Lexaria Bioscience | 7 |
| Intensity Therapeutics | 7 |
| Phio Pharmaceuticals | 6 |
| Hoth Therapeutics | 3 |
| Cyclerion Therapeutics | 1 |
ERNA News
- 2 days ago - Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 - GlobeNewsWire
- 6 days ago - Ernexa Therapeutics initiated with a Buy at Brookline - TheFly
- 6 days ago - 3 Penny Stocks to Watch Now, 5/7/26 - TipRanks
- 7 days ago - Ernexa Therapeutics announces new ERNA-101 preclinical data - TheFly
- 7 days ago - Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models - GlobeNewsWire
- 13 days ago - Ernexa Therapeutics announces 1-for-25 reverse stock split - TheFly
- 13 days ago - Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split - GlobeNewsWire
- 6 weeks ago - Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 - GlobeNewsWire